Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  leukemia
Stage/Subtype:  leukemia
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Trial Status:  Active
Results 1-19 of 19 for your search:
Start Over
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
Pneumococcal Vaccine in Untreated CLL Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 2009-012642-22, NCT01892618
Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 to 75
Sponsor: Other
Protocol IDs: 05/10-L, NCT01146262
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: H-30087 TAIL, NCT01604031
DC Vaccination for Postremission Therapy in AML
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2010-022446-24, NCT01734304
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-HM-001, NCT01744223
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-004, NCT02065869
DC Vaccination for Post-remission Therapy in AML
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CD-FDC-001, NCT02405338
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HaemaCBFWT102, Carreras 04/25f, NCT00153582
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J05121 CDR0000492005, P30CA006973, JHOC-J05121, J05121, NCT00363649
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 09-412, NCT01096602
Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-143, NCT01266083
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: CCRG12-001, NCT01686334
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 311-12-001, JapicCTI-142429, NCT01961882
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC138E, NCI-2014-02373, RV-CL-CLL-PI-003938, P30CA015083, NCT02309515
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: O5CC14, EudraCT 2005-000806-29, GTAC GTAC098, NCT00718250
Host Dendritic Cells in Allograft Patients
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 08-0906, NCT00935597
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: NCI, Other
Protocol IDs: 11-0545, NCI-2011-03588, NCT01842139
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NU 13H05, X12-11008, P30CA060553, NCT01976520
Start Over